{"id":"rnf","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RNF works by blocking the interaction between CD47 and SIRPα, which is a mechanism that cancer cells use to evade immune detection. This blockade allows the immune system to recognize and attack cancer cells more effectively.","oneSentence":"RNF is a small molecule targeting the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:32.443Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"},{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT05618834","phase":"NA","title":"Promoting Positive Care Interactions (PPCI) in Assisted Living","status":"ACTIVE_NOT_RECRUITING","sponsor":"Penn State University","startDate":"2025-03-03","conditions":"Alzheimer Disease and Related Dementias","enrollment":120},{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00813709","phase":"PHASE3","title":"Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-12","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":402},{"nctId":"NCT00110396","phase":"PHASE3","title":"Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-01","conditions":"Multiple Sclerosis","enrollment":260},{"nctId":"NCT01125475","phase":"","title":"A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-08","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":61},{"nctId":"NCT00441103","phase":"PHASE3","title":"A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":180},{"nctId":"NCT01110993","phase":"","title":"An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":65},{"nctId":"NCT00404352","phase":"PHASE3","title":"REbif FLEXible Dosing in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":517},{"nctId":"NCT00735007","phase":"PHASE3","title":"12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2008-07","conditions":"Multiple Sclerosis","enrollment":106},{"nctId":"NCT00428584","phase":"PHASE3","title":"RNF and Betaseron® Tolerability Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2006-12","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":129},{"nctId":"NCT00472797","phase":"PHASE3","title":"Rebif New Formulation (RNF) Quality of Life (QOL) Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-04","conditions":"Relapsing Multiple Sclerosis","enrollment":232}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"HYPERTENSION"},{"count":1,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rebif®","Rebif"],"phase":"phase_3","status":"active","brandName":"RNF","genericName":"RNF","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RNF is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma, Relapsed or refractory non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}